@entity263 accounts for only 3.6% of orbital metastases encountered in clinical practice. We report the clinical presentation and response to treatment of a @entity1 with metastatic @entity263 to the sella turcica. A 73-year-old @entity1 presented with a three-months history of progressive right proptosis associated with increasing @entity892 in down-gaze and slightly decreased visual acuity. @entity2287 -MRI scans of the head revealed a left osteoblastic intrasellar mass, displacing the pituitary gland. Laboratory testing revealed a serum @entity11179 level of 22 ng/ml. Transrectal ultrasound-guided biopsy revealed @entity263 (Gleason score 4+3) in both lobes of the prostate. A bone scan was performed showing that the @entity1 had @entity75 . Total @entity342 blockade was initiated. Moreover, he was referred for radiotherapy of this metastatic lesion to the sella turcica. The visual complaints regressed dramatically within the first month of the treatment. A follow-up MRI scan at 6 months showed almost complete involution of the orbital metastatic process. However the disease subsequently progressed and the @entity1 died 22 months after diagnosis.

Orbital metastasis as a first indication of XXXX : a case report.

@entity1 :: ('9606', 'Species') :: ['patient', 'man'] @entity263 :: ('MESH:D011471', 'Disease') :: ['Prostatic carcinoma', 'prostatic carcinoma', 'prostatic adenocarcinoma'] @entity75 :: ('MESH:D001927', 'Disease') :: ['multiple secondary bony lesions'] @entity11179 :: ('9520', 'Gene') :: ['PSA'] @entity342 :: ('CHEBI:50113', 'Chemical') :: ['androgen'] @entity892 :: ('MESH:D004172', 'Disease') :: ['diplopia'] @entity2287 :: ('MESH:D005682', 'Chemical') :: ['Gadolinium']
@entity263 :: (MESH:D011471,Disease) :: ['prostate cancer']
